Compare Regeneron Pharmaceuticals Inc (REGN) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Xylem, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Xylem, Inc. trades at $116 (market cap $27.81B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.5× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.47%). Which is the better fit depends on your goals.
| REGN | XYL | |
|---|---|---|
Market Cap | $70.79B | $27.81B |
Sector | Health | Industrials |
52-Week High | $812.27 | $152.95 |
52-Week Low | $545.46 | $106.34 |
Enterprise Value | $64.74B | $29.06B |
Dividend Yield | 0.56% | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
XYL trades at $117.00, down 4.71% today, amid mixed technical signals with a bullish overall trend but neutral oscillators. Fundamentally, the company shows steady revenue growth from $8.6B in 2024 to $9.04B in 2025, with net income margins improving to 10.79%. Recent earnings beats and a consistent dividend history support investor confidence, while analyst consensus leans slightly bullish with a $152.71 price target.
The outlook for XYL remains positive given its earnings momentum and strategic partnerships in water technology. Key risks include execution challenges in integrating new leadership and macroeconomic pressures on industrial spending. The stock offers potential upside to analyst targets but requires monitoring of upcoming Q2 2026 results due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
